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Birdshot chorioretinopathy (BSCR) is a rare form of autoimmune posterior uveitis that can affect the visual function and, if left
untreated, can lead to sight-threatening complications and loss of central vision. We performed a systematic search of the literature
focused on visual electrophysiology studies, including electroretinography (ERG), electrooculography (EOG), and visual evoked
potentials (VEP), used to monitor the progression of BSCR and estimate treatment efficacy. Many reports were identified, including
using a variety of methodologies and patient populations, which makes a direct comparison of the results difficult, especially with
some of the earlier studies using nonstandardized methodology. Several different electrophysiological parameters, like EOG Arden’s
ratio and the multifocal ERG response densities, are reported to be widely affected. However, informal consensus emerged in the past
decade that the full-field ERG light-adapted 30 Hz flicker peak time is one of the most sensitive electrophysiological parameters. As
such, it has been used widely in clinical trials to evaluate drug safety and efficacy and to guide therapeutic decisions in clinical
practice. Despite its wide use, a well-designed longitudinal multicenter study to systematically evaluate and compare different
electrophysiological methods or parameters in BSCR is still lacking but would benefit both diagnostic and therapeutic decisions.

1. Introduction
Birdshot chorioretinopathy (BSCR) (ICD-9 363.20) is a rare
form of slowly progressive, potentially blinding, bilateral posterior uveitis, likely of autoimmune origin, in which multiple
hypopigmented choroidal lesions are scattered throughout
the posterior pole. The term “birdshot retinopathy” was
officially proposed by Ryan and Maumenee in 1980 based on
the characteristic fundus appearance [1], although it is likely
that description of the same condition was available before
that, probably as early as 1949 [2]. The presence of the disease
is strongly associated with the most prevalent subtypes of the
human leucocyte antigen- (HLA-) A∗ 29 in Caucasians [3];
however, the role of this antigen in the pathophysiology of the
disease is uncertain and, therefore, its presence is not essential
for the establishment of BSCR diagnosis [4]. The disease is
relatively uncommon, with an estimated occurrence in ∼3%
of all uveitis patients [5] and 6–8% of patients with posterior
uveitis [2], affecting slightly more females (54–58%) than
males in their 50s or 60s [2, 6]. It can include a variety
of ocular complications, with the most frequent ones being

macular edema in 50% and optic disc edema in 24% of
the patients [2]. In more than 90% of the cases, both eyes
are symmetrically involved and the densest concentration
of lesions is around the optic disc, while few can be seen
in the macula. There is also a tendency for the lesions to
progress into large areas of choroidal depigmentation and in
61% of the cases narrowing of the retinal arteries is noted
[7]. In addition, retinal vasculitis is often present, primary as
phlebitis in the posterior pole [8] often detected as a vascular
leakage on fluorescein angiography [7].
The pathogenesis of the disease is still poorly understood.
Only two histological reports have been published indicating
that the hypopigmented choroidal lesions represent nodules
of lymphocyte aggregation, a sign of nongranulomatous
nodular infiltration of the choroid [9, 10]. The application of
enhanced depth imaging in spectral-domain optic coherence
tomography (SD-OCT) showed recently significant choroidal
thinning and disruption of the outer retinal substructures in
extramacular locations [11].
Treatment of BSCR involves oral and periocular corticosteroids, which can be effective in the short-term and
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Figure 1: Diagram of the six basic ERGs defined by the ISCEV Standard. These waveforms are exemplary only and are not intended to indicate
minimum, maximum, or typical values. Bold arrowheads indicate the stimulus flash; solid arrows illustrate a-wave and b-wave amplitudes;
dotted arrows exemplify how to measure time to peak (𝑡, implicit time or peak time) (to be reprinted with permission from McCulloch et al.
ISCEV Standard for full-field clinical electroretinography (2015 update) [17]. Documenta Ophthalmologica: Advances in Ophthalmology. 2015,
130(1): 1–12.)

during the early stages of the disease. Additionally, various
immunosuppressants, such as cyclosporine, azathioprine,
and cyclophosphamide, have been tried as long-term therapy
with mixed results [2].
Visual function can be affected in a variety of different
ways in BSCR. Central visual acuity is generally preserved
to 20/40 or better in at least 62% of the eyes; however,
blurred vision is reported in more than 80%, nyctalopia
in 17.5%, and dyschromatopsia in 8.7% of the cases [2].
Contrast sensitivity changes were found in 92% of the 63
patients (126 eyes) in a single center, cross-sectional study
and were related to poor central visual acuity [12]. Various
visual field abnormalities, including visual field constriction,
generalized diminished sensitivity, and enlarged blind spot,
have also been reported [2, 13]. More advanced central
visual field testing by microperimetry also showed decreased
retinal sensitivity even in patients with inactive disease [14],
suggesting that, despite the clinical impression of remission,
retinal sensitivity is still affected and does not recover completely. This discrepancy between clinical impressions based
on subjective symptoms and imaging methods on one hand
and deficits in visual function support the need for the use
of objective methods to evaluate vision function status and
inform treatment choices and decisions.
It is generally believed that visual electrophysiological
testing could detect early changes and could be used to
track the disease progression in uveitis and other retinal
inflammatory diseases [15, 16]. However, a more comprehensive look at the value and findings of such tests in BSCR
is still lacking. This review is focused on the use of visual
electrophysiological tests, like electroretinography (ERG),
electrooculography (EOG), visual evoked potentials (VEP),
and so forth, in BSCR. As objective and quantifiable testing
methods, these tests have the potential to be used as measures
to track the progression of the BRCS and estimate the efficacy
of current or prospective therapeutic approaches.

2. Materials and Methods
The literature search included the online sources PubMed,
Web of Science, and Embase from 1980 to February 2015.
Only references published in English were included. Case
reports were excluded.

3. Results and Discussion
3.1. Electroretinography. The electroretinogram (ERG) is a
recording of the bioelectrical response of the eye from a brief
light stimulation. The three types most used in the clinic are
full-field ERG, pattern ERG (PERG), and multifocal ERG
(mfERG).
3.1.1. Full-Field ERG. The full-field ERG is a retinal response
to a diffuse brief (typically less than 5 milliseconds) illumination of the whole retina. As an objective measure of the
retinal function, it is well suited not only for tracking the
effect of retinal disease progression on the visual function,
but also for estimating the efficacy and safety of therapies
either at drug development stage or in postmarketing studies
[18]. For clinical purposes, this test is most often recorded
in compliance with an international standard for full-field
ERG recording established by the International Society for
Clinical Electrophysiology of Vision (ISCEV), first published
in 1989 and regularly updated after that [17, 19]. The current
edition of the ISCEV Standard recommends as a protocol the
collection of four dark-adapted and two light-adapted types
of responses and prescribes how the responses are recorded,
measured, analyzed, and reported (Figure 1).
At least 21 peer-reviewed articles (Table 1) have been published using some parameters of the full-field ERG to support
diagnostic or therapeutic decisions in the management of
BSCR since 1980. Some of the early works [8, 20–22] provide
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very little detail about the ERG methodology and that makes
it difficult to compare their findings with more recent studies.
Although a variety of ERG parameters have been reported to
be affected in different ways, from supernormal responses at
the early stages to greatly diminished and delayed or even
absent responses at late stages, an informal consensus has
emerged about 10 years ago that the light-adapted 30 Hz
flicker response is the most sensitive one [23–25] and it has
since then been used as an outcome measure in clinical
trials testing drug effectiveness in this condition [26–28].
Therefore, the following analysis of studies reporting fullfield ERG results will be centered on reported changes in this
response.
The first better documented study in terms of ERG
methodology detailed by Fuerst et al. [29] demonstrated
for the first time that ERG 30 Hz flicker peak time is
prolonged significantly and more than any other peak time
ERG parameter in all six patients participating intuit study.
Few years later, Hirose et al. [30] studied 15 patients (28
eyes) and concluded that several parameters: the scotopic bwave, the photopic b-wave, and the 30 Hz flicker response,
were all affected in at least 50% of the eyes. They did not
measure (or at least report) 30 Hz flicker peak time. It is
worth pointing out that all of the above-mentioned works,
as well as some more recent ones [31–33], did not use a
methodology fully compliant with the ISCEV Standard. That
makes it very difficult to compare directly results between
different studies and to make conclusions about comparative
diagnostic and/or management utility of the different ERG
parameters used.
In 2002, the first work evaluating full-field ERG as an
indicator of disease activity and using a recording protocol
conforming to the ISCEV Standard was published by Zacks et
al. [23]. The authors compared seven parameters of the ERG
responses from 15 HLA-A29-positive BSCR patients (30 eyes)
at age 29–69, who were on immunosuppressive medication
and had three serial ERG recordings. They correlated the ERG
parameters with the success in tapering immunosuppressive
therapy and concluded that the ERG parameter that showed
the most significant correlation with an inability to taper
medication was the light-adapted 30 Hz flicker implicit time
(𝑝 < 0.01). The only other parameter that reached statistical
significance in that comparison was the combined rod-cone
ERG b-wave amplitude (𝑝 < 0.05). Given the relatively small
number of patients involved, the fact that two out of the
seven ERG parameters reached statistical significance was an
indication of the potential of this test to be used in monitoring
the therapeutic effectiveness in BSCR.
More support for the idea that the 30 Hz ERG flicker
response may be useful in BSCR came in 2005 with the work
of Holder et al. [24], who used a variety of ERG parameters
(standard and some nonstandard) in a cohort of 18 patients
with BSCR (age: 26–64 years). Nine out of 10 patients who had
systemic treatment with steroids and/or immunosuppressant
drugs and serial ERG recordings showed improvement in
some ERG parameters. The authors concluded that the most
sensitive ERG parameter was the light-adapted 30 Hz flicker
implicit time in direct confirmation to the previous findings
of Zacks et al.
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The only other detailed study from the same period with a
main goal to evaluate the use of ERG in monitoring BSCR was
that of Sobrin et al. [25], who studied 23 BSCR patients (age
range: 39–75) over the course of several years (up to 7 years).
Although the authors concluded in their Discussion that “the
best parameter to detect improvement during treatment is
not clear,” their data show a very significant effect on lightadapted 30 Hz flicker peak time as a delayed response (𝑝 <
0.001) at baseline and during observed intervals without
treatment (𝑝 = 0.001). Only 9 patients (18 eyes) out of the 23
had more than one ERG follow-up during treatment; in this
subset, the ERG parameter that showed the most significant
change was the 30 Hz flicker amplitude (𝑝 = 0.002), while
the 30 Hz flicker peak time did not show significant change
(𝑝 = 0.13). The lack of change in 30 Hz flicker peak time may
be due to the insufficient number of subjects, short time of
observation, and so forth.
Since then, two other studies showed also delay in 30 Hz
flicker peak time in BSCR patients. Kiss et al. studied 28
patients, who were followed up every 6 months with ERG
[34]. They reported that 58% of the patients had delayed
30 Hz flicker peak time at the initial visit and 62.5% at the
final visit. Sobrin et al. did retrospective analysis of the
ERG records in 8 patients (16 eyes) treated with intravenous
application of daclizumab at 2-week intervals for 25-month
period [35]. They found that the ERG 30 Hz peak times were
further delayed by 2 milliseconds or more at the last available
ERG for each patient in 4 eyes, including two eyes of two
patients with adequate inflammation control.
Furthermore, four studies used this parameter in monitoring the therapeutic efficacy in BSCR, either as part
of the clinical definition of relapse/inflammation control
(infliximab therapy) [27], as part of the overall management
decision process [26, 28] (fluocinolone, cyclosporine A,
and mycophenolate), or as a secondary outcome measure
[36] (mycophenolate). However, only two studies [27, 36]
reported statistical results indicating that 30 Hz flicker peak
times were significantly shorter at the end of the follow-up
period, in parallel with improvement in angiographic and
clinical signs.
Another aspect of the full-field ERG changes in BSCR
is the dependence of the ERG changes on the stage of the
disease, for example, in early versus late disease. This aspect
has not been explored in detail and only very few studies have
adequate information covering this relationship, as the natural course of the disease is uncertain. One such work is the
study by Hirose et al. [30] based on the results of 15 patients
(28 eyes) where the authors reported the effects of duration
of disease on ERG parameters. Generally, they find decline
in the a-wave and b-wave amplitudes with progression of
the disease, without providing a correlation coefficient. They
estimate two groups of patients: one with acute decline in
retinal function and one with more gradual decline in retinal
function. Thus, it is likely that ERG amplitudes reflect the
state of the retina related to the stage of the disease.
3.1.2. Pattern ERG. Pattern ERG (PERG) reflects ganglion
cell activity in the central retina. Thus, similar to visual
field changes in BRCS as described above, PERG would
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be expected to demonstrate negative changes (decrease in
amplitude or delay in peak time) reflecting the current
functional status of the macula. Very few studies have been
published using PERG in BSCR. Thus, Holder et al. recorded
pattern ERG in 18 patients in parallel with full-field ERG
[24]. In most patients, PERG changes were similar to the fullfield ERG changes in terms of amplitude decrease and peak
time delay and were correlated with color contrast sensitivity
changes.
3.1.3. Multifocal ERG. The multifocal ERG (mfERG) represents an array of local, cone-driven responses from the central
20 to 30 degrees of the retina [37]. The main contribution of
the mfERG signal comes from bipolar cells, with smaller contributions from amacrine or ganglion cells [38, 39]. Only two
reports have been published to date using mfERG in BRCS.
Birch et al. [40] reported that 6 eyes with anatomical thinning
in the macula, both in terms of reduction in total retinal
thickness and outer retinal thickness and defined by SDOCT, had significantly lower mfERG responses compared
to 8 eyes without anatomical thinning and all eyes with a
history of BRCS for more than 10 years had abnormal mfERG
response densities. In a more recent study, Chiquet et al.
reported significant decrease in amplitudes and prolongation
of peak times in 28 patients with BRCS and these changes
were well correlated with visual acuity, mean defect of visual
field, foveal threshold, and color vision score and with
fluorescein angiography results [41]. These two studies clearly
demonstrate the potential of mfERG as an objective test of the
central retinal function in BR, although more comprehensive
studies would be clearly beneficial, especially comparing how
the mfERG changes reflecting macular function compare
with extramacular changes, which would be better reflected
in full-field ERG.
3.2. Electrooculography. Electrooculography is a technique
for measuring the standing potentials of the eye, generated
mostly in the retinal pigment epithelium (RPE) cells [42].
As the choroidal lesions, which represent a hallmark of the
disease, are located directly below the RPE, it is expected
that EOG would be affected. Indeed, in a review article
about BRCS, Shah et al. summarized the results of six studies
applying EOG including a total of 170 eyes and estimated that
66% of the tests had abnormal Arden ratios, the main EOG
parameter [2]. However, EOG has not been used as a test to
follow BRCS progression since the mid-80s, probably because
of low sensitivity and variability of the responses.
3.3. Visual Evoked Potential. Visual evoked potentials (VEP)
are visually evoked signals extracted from the EEG activity
in the visual cortex recorded from the overlying scalp, most
often as a result of a flash or pattern stimulation. As flash VEP
amplitude shows a large degree of interindividual variability,
pattern VEP recorded typically to central 15 degree reversing
monochrome pattern stimulus is currently preferred for
clinical standardized testing [43]. Priem and Oosterhuis
[7] reported abnormal flash VEP amplitudes in 53% and
increased latency in 22% of 30 patients (60 eyes) tested
with BSCR. Priem et al. [21] reported affected pattern VEP
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responses as reduced amplitudes and prolonged peak times
in most of the 16 patients (32 eyes) that they tested. In the
same patients, they found normal flash VEP responses. No
studies have been published after the introduction of the
first edition of the International standard for VEP recording
[44] and, thus, it is presently unclear whether standardized
recordings may improve the sensitivity or specificity of the
VEP responses.

4. Discussion
Although many studies have been conducted over the years,
there is still some uncertainty and ambiguity regarding the
best electrophysiological method (or a specific parameter
within a method) to quantify changes in retinal function
associated with the course of BRCS. One of the reasons for
that is the scarcity of experimental models of BRCS. Another
reason is that some ERG responses are smaller and difficult
to record in mice, the most widely used species for animal
models of posterior uveitis. This is the case with the photopic
30 Hz flicker response and, to the best of our knowledge, no
studies have been published demonstrating changes in this
response in mouse models of uveitis. However, other ERG
parameters have been successfully used in animal models
and have been shown to be an effective objective indicator
of retinal function and in monitoring the disease progression
and therapeutic safety and efficacy [45–47].
The cellular mechanism responsible for the high sensitivity of 30 Hz flicker ERG response to retinal changes
caused by BRCS is currently unknown. Several hypotheses
can be put forward to explain the observed relatively strong
correlation between clinical disease progression and this
type of ERG response. One such hypothesis would place
emphasis on the fact that, for the retina to be able to
follow precisely the relatively fast 30 Hz flicker stimulation,
its metabolic and physiological pathways have to operate at
higher rate and any disturbance in it would result in degraded
performance. Such a hypothesis is supported indirectly by
the documented decline in flicker fusion frequency observed
electrophysiologically in experimental posterior uveitis [48],
although studies in BRCS are lacking. Similar sensitivity of
the 30 Hz flicker ERG response to progression of a vascular
retinal disease is reported in central retinal vein occlusion
(CRVO) for dark- [49, 50] and light-adapted flicker response
[51, 52] and also in branch retinal vein occlusion (BRVO) [53].
Of note, although the highest concentration (density) of
cone photoreceptors and cone bipolar cells is in the fovea,
the overall number of cone photoreceptors in the fovea is
only about 200,000 or ∼4% of the total number of cone
photoreceptors in the retina [54, 55]. As the 30 Hz flicker
response is generated predominantly by cone bipolar cells
[56–58], it should not be surprising that this parameter is
sensitive to a disease that demonstrated pathological changes
mostly in retinal periphery. On the other hand, this can
explain the lack of correlation between ERG parameters and
central visual field (Humphrey Visual Field 24-2) changes
in a recent longitudinal study in BSCR [59]. Of note, 30 Hz
flicker peak time was also the most affected ERG parameter.
On the other hand, the question sometimes arises as why
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visual function in the macula can be affected as detected
by PERG or mfERG, especially in cases without macular
edema, while most of the lesions are extramacular. In this
context, localized pathological changes in the choroid can
have widespread visual function effects, often extending
beyond the circumscribed choroidal lesion, as has been
demonstrated in experimental photodynamic therapy [60].
The full-field ERG records a mass response reflecting
activity throughout the retina and is dominated by signals
coming from the retinal periphery. As most of the observable
changes in BSCR are also located in the periphery, it would
be expected that full-field ERG parameters would be more
sensitive to disease progression, compared to electrophysiological tests of more central retinal function, like PERG and
standard mfERG, although a detailed comparison between
the three methods is not available. Thus, it may be expected
that full-field ERG parameters, like the 30 Hz flicker response,
will continue to play an important role in the evaluation of
retinal function in BSCR in the near future. A more sensitive
(and specific?) test may be wide field mfERG, either alone or
in combination with full-field ERG [61].
In summary, there is large clinical evidence and precedent
(based on results from more than 200 patients) to support the
use of light-adapted 30 Hz flicker ERG response as an outcome measure in clinical trials involving BSCR and in clinical
practice. When recording this response, both amplitude and
implicit time are parameters that are available and it may be
beneficial to record and analyze both parameters.
However, it has to be kept in mind that some large studies
with a long follow-up period have been inconclusive [25] and
the majority of the 30 Hz ERG results are reported from only
a few centers. This is understandable, as BSCR is a relatively
rare disease and recruitment of a sizeable number of patients
can be a challenge by a single center. Another limitation is
that the direct effect of immunosuppressive therapy, often
used in BSCR, on the ERG signal (including 30 Hz flicker)
has not been reported. As systematic studies are lacking, some
caution should be applied and this should be investigated in
future studies.
At present, a well-designed multicenter study to systematically evaluate and compare different electrophysiological
methods or parameters in BSCR bases on sensitivity and
specificity is still lacking. Such a study could be very useful
in providing an objective assessment of retinal function
during the course of the disease and help evaluating the
overall treatment efficacy and the dosing regimen of newly
developed or established pharmaceutical agents.

5. Conclusions
Various visual electrophysiology tests have been used over the
years to document various vision function changes in BRCS
and many of them show different degree of abnormality.
Historically, the photopic 30 Hz flicker peak time of the fullfield ERG has emerged as the most popular parameter to
follow the disease progression and estimate the success of
treatment. The exact mechanism behind the observed 30 Hz
peak time delay in BRCS is unclear. It also remains uncertain
whether this is truly the mist sensitive parameter, which can
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be only established with a large, longitudinal, multicenter
study to evaluate the value of different electrophysiological
methods or parameters. Until then, there is enough evidence
to recommend the use of photopic 30 Hz flicker in the clinical
management of BSCR.
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